NFE2L2 and pemphigus foliaceus: As an FDA-approved anti-fibrotic medication for the treatment of IPF, pirfenidone effectively impedes the progression of BLM-induced PF by upregulating the expression levels of Nrf2, HO-1, and GPX1 [64].